Skip to main content

Commercial & Research Opportunity for Cysteinyl Leukotriene Signalling in Ocular & CNS Dysfunction, Cancer and Cardiovascular Disease

Objective

Cysteinyl leukotrienes (CysLTs) are potent lipid mediators of inflammation. CysLT1 and 2 receptors are widely expressed e.g. lungs, colorectum, heart, brain & eye; and CysLT1 antagonists are prescribed to treat airway inflammation. Excitingly, CysLT signalling was recently discovered to regulate the biology of vascular, neuronal and cancer cells underpinning its untapped therapeutic potential in other diseases. CRYSTAL3 interconnects unique and diverse researchers to create a multidisciplinary team sharing expertise and research capacities. The contribution of CysLT signalling to disease is divulged; its therapeutic potential unlocked and new services & products commercialised. This is delivered by staff exchanges to jointly research Ocular & Central Nervous System (CNS), Cardiovascular system (CV) and Cancer diseases.
The R&I goal of CRYSTAL3 is to reduce human disease burden by enhancing EU capability and knowledge-sharing in research and commercialisation. This is achieved through advanced international co-operation between 5 academic and 5 non-academic partners, in 7 countries. The focus is on innovative research into the CysLT signalling pathway in human diseases related to the Ocular-CNS, & CV systems and Cancer (OCCC).

The 3 overall objectives of CRYSTAL3 are:
A) Combine resources to discover novel pathological mechanisms linking cysteinyl leukotriene signalling to ocular, central nervous system, cardiovascular disease and cancer (OCCC).
B) Unite partner capacities to uncover the therapeutic potential of cysteinyl leukotriene signalling in ocular, central nervous system, cardiovascular disease and cancer (OCCC).
C) Commercialise products and services co-developed within CRYSTAL3

The CRYSTAL3 consortium tackles these challenges by promoting cross-sector, inter-European R&I staff exchanges among participants with expertise in OCCC disease, computational drug discovery, genetic engineering, pre-clinical disease models, marketing and commercialisation.

Field of science

  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/medical biotechnology/genetic engineering

Call for proposal

H2020-MSCA-RISE-2020
See other projects for this call

Funding Scheme

MSCA-RISE - Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE)

Coordinator

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Address
Belfield
4 Dublin
Ireland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 133 400

Participants (9)

THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
Ireland
EU contribution
€ 170 200
Address
College Green
2 Dublin
Activity type
Higher or Secondary Education Establishments
LINKOPINGS UNIVERSITET
Sweden
EU contribution
€ 82 800
Address
Campus Valla
581 83 Linkoping
Activity type
Higher or Secondary Education Establishments
UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS
Germany
EU contribution
€ 32 200
Address
Robert-koch-strasse 40
37075 Goettingen
Activity type
Higher or Secondary Education Establishments
XENOPAT SL
Spain
EU contribution
€ 13 800
Address
Calle Feixa Llarga S/n Edifici Bioincuoadora
08907 Hospitalet De Llobregat
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
OCUPHARM DIAGNOSTICS SL
Spain
EU contribution
€ 377 200
Address
Francisco Silvela 88 7B
28002 Madrid
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
PHARMAHUNGARY 2000 KISERLETES ES KLINIKAI KUTATASFEJLESZTESI KORLATOLTFELELOSSEGU TARSASAG
Hungary
EU contribution
€ 36 800
Address
Hajnoczy Utca 6 1 Em 1
6722 Szeged
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
BIOREPERIA AB
Sweden
EU contribution
€ 4 600
Address
Westmansgatan 47 3Tr
582 16 Linkoping
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
CRESSET BIOMOLECULAR DISCOVERY LIMITED
United Kingdom
EU contribution
€ 13 800
Address
New Cambridge House Bassingbourn Road
SG8 0SS Litlington
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
LABORATORIO IBERICO INTERNACIONAL DE NANOTECNOLOGIA
Portugal
EU contribution
€ 23 000
Address
Avenida Mestre Jose Veiga
4715-330 Braga
Activity type
Research Organisations